ELVN logo

Enliven Therapeutics, Inc. (ELVN) EBITDA

Annual EBITDA:

-$104.24M-$21.00M(-25.24%)
December 31, 2024

Summary

  • As of today, ELVN annual EBITDA is -$104.24 million, with the most recent change of -$21.00 million (-25.24%) on December 31, 2024.
  • During the last 3 years, ELVN annual EBITDA has fallen by -$79.59 million (-322.92%).
  • ELVN annual EBITDA is now -332.82% below its all-time high of -$24.08 million, reached on December 1, 2019.

Performance

ELVN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNincome statement metrics

Quarterly EBITDA:

-$25.03M+$3.47M(+12.17%)
September 30, 2025

Summary

  • As of today, ELVN quarterly EBITDA is -$25.03 million, with the most recent change of +$3.47 million (+12.17%) on September 30, 2025.
  • Over the past year, ELVN quarterly EBITDA has increased by +$1.95 million (+7.24%).
  • ELVN quarterly EBITDA is now -668.62% below its all-time high of -$3.26 million, reached on December 31, 2022.

Performance

ELVN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNincome statement metrics

TTM EBITDA:

-$111.97M+$1.95M(+1.72%)
September 30, 2025

Summary

  • As of today, ELVN TTM EBITDA is -$111.97 million, with the most recent change of +$1.95 million (+1.72%) on September 30, 2025.
  • Over the past year, ELVN TTM EBITDA has dropped by -$11.90 million (-11.89%).
  • ELVN TTM EBITDA is now -1528.92% below its all-time high of -$6.87 million, reached on September 1, 2019.

Performance

ELVN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

ELVN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-25.2%+7.2%-11.9%
3Y3 Years-322.9%-130.2%-161.7%
5Y5 Years-332.8%-100.8%-272.3%

ELVN EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-322.9%at low-668.6%+20.8%-252.8%+1.7%
5Y5-Year-332.8%at low-668.6%+20.8%-272.3%+1.7%
All-TimeAll-Time-332.8%at low-668.6%+20.8%-1528.9%+1.7%

ELVN EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$25.03M(+12.2%)
-$111.97M(+1.7%)
Jun 2025
-
-$28.50M(+9.9%)
-$113.93M(-3.6%)
Mar 2025
-
-$31.62M(-17.9%)
-$109.95M(-5.5%)
Dec 2024
-$104.24M(-25.2%)
-$26.82M(+0.6%)
-$104.24M(-4.2%)
Sep 2024
-
-$26.99M(-10.0%)
-$100.07M(-2.9%)
Jun 2024
-
-$24.52M(+5.3%)
-$97.25M(-4.8%)
Mar 2024
-
-$25.91M(-14.4%)
-$92.79M(-11.5%)
Dec 2023
-$83.23M(-147.4%)
-$22.65M(+6.3%)
-$83.23M(-30.4%)
Sep 2023
-
-$24.17M(-20.5%)
-$63.84M(-26.3%)
Jun 2023
-
-$20.06M(-22.7%)
-$50.54M(-28.1%)
Mar 2023
-
-$16.35M(-402.0%)
-$39.45M(-24.3%)
Dec 2022
-$33.65M
-$3.26M(+70.0%)
-$31.73M(+25.8%)
Sep 2022
-
-$10.87M(-21.3%)
-$42.79M(+6.1%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$8.96M(-3.8%)
-$45.55M(+8.4%)
Mar 2022
-
-$8.64M(+39.6%)
-$49.73M(+3.1%)
Dec 2021
-$24.65M(+40.8%)
-
-
Dec 2021
-
-$14.31M(-4.9%)
-$51.34M(-5.7%)
Sep 2021
-
-$13.63M(-3.7%)
-$48.56M(-2.5%)
Jun 2021
-
-$13.14M(-28.2%)
-$47.40M(-6.4%)
Mar 2021
-
-$10.26M(+11.0%)
-$44.53M(-7.0%)
Dec 2020
-$41.60M(-72.7%)
-$11.53M(+7.6%)
-$41.60M(-38.3%)
Sep 2020
-
-$12.47M(-21.3%)
-$30.07M(-22.9%)
Jun 2020
-
-$10.28M(-40.2%)
-$24.48M(-72.4%)
Mar 2020
-
-$7.33M(-6.6%)
-$14.20M(-106.6%)
Dec 2019
-$24.08M
-
-
Sep 2019
-
-$6.87M
-$6.87M

FAQ

  • What is Enliven Therapeutics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. annual EBITDA year-on-year change?
  • What is Enliven Therapeutics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. quarterly EBITDA year-on-year change?
  • What is Enliven Therapeutics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. TTM EBITDA year-on-year change?

What is Enliven Therapeutics, Inc. annual EBITDA?

The current annual EBITDA of ELVN is -$104.24M

What is the all-time high annual EBITDA for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high annual EBITDA is -$24.08M

What is Enliven Therapeutics, Inc. annual EBITDA year-on-year change?

Over the past year, ELVN annual EBITDA has changed by -$21.00M (-25.24%)

What is Enliven Therapeutics, Inc. quarterly EBITDA?

The current quarterly EBITDA of ELVN is -$25.03M

What is the all-time high quarterly EBITDA for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high quarterly EBITDA is -$3.26M

What is Enliven Therapeutics, Inc. quarterly EBITDA year-on-year change?

Over the past year, ELVN quarterly EBITDA has changed by +$1.95M (+7.24%)

What is Enliven Therapeutics, Inc. TTM EBITDA?

The current TTM EBITDA of ELVN is -$111.97M

What is the all-time high TTM EBITDA for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high TTM EBITDA is -$6.87M

What is Enliven Therapeutics, Inc. TTM EBITDA year-on-year change?

Over the past year, ELVN TTM EBITDA has changed by -$11.90M (-11.89%)
On this page